BioSpace News Archive

Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced its financial calendar for 2020.

Organization is the only cancer center in state of Florida included in list

The founders of United Medical Credit are pleased to announce that they are now able to offer IVF financing to people with approved credit thanks to new Lending Relationships.

Gollapalli brings more than 20 years of nonprofit fundraising experience

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone grafting products used for bone fusion procedures, announced today that 2019 has been its best sales year in company history

After performing a three-day rigorous inspection measuring MEDISCA’s compliance in Good Manufacturing Practices (GMPs) and other standards for quality control, Health Canada has distinguished MEDISCA with a “Compliant” rating

In response to today’s announcement of Trump administration proposals to allow importation of certain prescription drugs, the American Pharmacists Association (APhA) today expressed its overwhelming concerns for patient safety.

Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company discovering and developing highly-differentiated therapies, today announced a clinical collaboration with Genentech, a member of the Roche group, for the evaluation of novel combinations with AB928, Arcus’s dual antagonist of adenosine receptors A2aR and A2bR, for colorectal (CRC) and pancreatic (PDAC) cancers.